-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-05-15
Values as of: 2024-05-15
The investment seeks investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index. In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Company Website : www.spdrs.com
Currency: USD
Country : USA
Inception Date: 16/12/1998
Primary Benchmark: S&P Health Care Select Sector TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.15%
Management Expense Ratio: 0.13 %
N/A
N/A
Symbol | Company Name | Allocation |
---|---|---|
LLY | Eli Lilly and Company | 12.91 % |
UNH | UnitedHealth Group Incorporated | 9.45 % |
JNJ | Johnson & Johnson | 7.23 % |
ABBV | AbbVie Inc | 6.01 % |
MRK | Merck & Company Inc | 4.89 % |
TMO | Thermo Fisher Scientific Inc | 3.99 % |
ABT | Abbott Laboratories | 3.69 % |
ISRG | Intuitive Surgical Inc | 3.29 % |
AMGN | Amgen Inc | 3.07 % |
DHR | Danaher Corporation | 2.98 % |
N/A
N/A
Symbol | Name | Mer | Price(Change) | Market Cap |
---|---|---|---|---|
FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
-0.13 (-0.18%) |
USD 2.86B |
FXH | First Trust Health Care AlphaD.. | 0.63 % |
+0.33 (+0.31%) |
USD 1.18B |
XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
+0.24 (+0.27%) |
USD 0.21B |
IDNA | iShares Genomics Immunology an.. | 0.00 % |
+0.08 (+0.32%) |
USD 0.14B |
SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
-0.53 (-1.37%) |
USD 0.12B |
XHS | SPDR® S&P Health Care Service.. | 0.35 % |
-1.28 (-1.35%) |
USD 0.08B |
HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
+0.12 (+0.43%) |
USD 0.05B |
BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
-0.56 (-0.87%) |
USD 0.02B |
BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
-0.55 (-1.87%) |
USD 0.01B |
IHE | iShares U.S. Pharmaceuticals E.. | 0.42 % |
-0.73 (-1.04%) |
N/A |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
HYLG | Global X Funds - Global X.. | 53.23 % | 0.00 % |
-0.05 (0.15%) |
N/A |
CLSM | Cabana Target Leading Sec.. | 30.09 % | 0.00 % |
-0.12 (0.15%) |
USD 0.16B |
TDSC | Cabana Target Drawdown 10.. | 15.22 % | 0.00 % |
-0.04 (0.15%) |
USD 0.21B |
TACK | Fairlead Tactical Sector .. | 11.81 % | 0.00 % |
-0.04 (0.15%) |
USD 0.22B |
SSUS | Day Hagan/Ned Davis Resea.. | 10.72 % | 0.00 % |
-0.22 (0.15%) |
USD 0.61B |
THLV | THOR Financial Technologi.. | 9.80 % | 0.00 % |
-0.03 (0.15%) |
USD 0.08B |
AESR | 9.73 % | 0.00 % |
N/A |
N/A | |
PSTR | PeakShares Sector Rotatio.. | 9.45 % | 0.00 % |
+0.04 (+0.15%) |
USD 0.01B |
QPX | AdvisorShares Q Dynamic G.. | 6.02 % | 0.00 % |
-0.23 (0.15%) |
USD 0.03B |
TDSB | Cabana Target Drawdown 7 .. | 4.89 % | 0.00 % |
-0.02 (0.15%) |
USD 0.09B |
HAC:CA | Global X Seasonal Rotatio.. | 4.39 % | 1.27 % |
-0.14 (0.15%) |
CAD 0.22B |
LCR | Leuthold Core ETF | 4.20 % | 0.00 % |
-0.06 (0.15%) |
USD 0.09B |
EQL | ALPS Equal Sector Weight .. | 0.00 % | 0.15 % |
-0.08 (0.15%) |
N/A |
FUT:CA | 0.00 % | 0.81 % |
N/A |
N/A | |
QGTA | 0.00 % | 0.37 % |
N/A |
N/A | |
QLS | 0.00 % | 0.76 % |
N/A |
N/A | |
EQL | ALPS Equal Sector Weight .. | 0.00 % | 0.26 % |
-0.08 (0.15%) |
N/A |
EQL | ALPS Equal Sector Weight .. | 0.00 % | 0.26 % |
-0.08 (0.15%) |
N/A |
XLSR | SPDR® SSGA U.S. Sector R.. | 0.00 % | 0.00 % |
-0.20 (0.15%) |
USD 0.62B |
USHG | 0.00 % | 0.00 % |
N/A |
N/A | |
FATT | 0.00 % | 0.00 % |
N/A |
N/A | |
RSPY | 0.00 % | 0.00 % |
N/A |
N/A | |
RRH | 0.00 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 7.20% | 81% | B- | 62% | D | ||
Dividend Return | 0.38% | 83% | B | 21% | F | ||
Total Return | 7.58% | 86% | B+ | 59% | D- | ||
Trailing 12 Months | |||||||
Capital Gain | 11.59% | 90% | A- | 54% | F | ||
Dividend Return | 1.68% | 100% | F | 24% | F | ||
Total Return | 13.27% | 90% | A- | 49% | F | ||
Trailing 5 Years | |||||||
Capital Gain | 65.31% | 100% | F | 75% | C | ||
Dividend Return | 8.53% | 94% | A | 30% | F | ||
Total Return | 73.84% | 100% | F | 75% | C | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 9.86% | 90% | A- | 70% | C- | ||
Dividend Return | 11.08% | 100% | F | 67% | D+ | ||
Total Return | 1.21% | 89% | A- | 29% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 10.73% | 90% | A- | 80% | B- | ||
Risk Adjusted Return | 103.27% | 100% | F | 98% | N/A | ||
Market Capitalization | 13.53B | 100% | F | 94% | A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
There is nothing we particularly dislike